H.C. Wainwright reiterates Syndax stock Buy rating at $38 target

H.C. Wainwright reiterated its Buy rating on Syndax Pharmaceuticals with a $38 price target, implying more than 100% upside from the $18.80 share price, following diligence on Revuforj's NPM1m AML opportunity. The firm identified treatment-sequencing headwinds from actionable co-mutations and established targeted therapies, though not specifically from competing menin inhibitors. Syndax's Q2 2026 revenue rose 92% year over year, including $54.7 million from Revuforj and $18.1 million in Niktimvo collaboration revenue, but the company missed earnings and revenue expectations, prompting BofA and UBS price-target cuts.

Analysis

SNDX’s valuation hinge is shifting from label-driven optionality to proof of durable patient-start growth. A sequential slowdown in Revuforj starts matters more than headline revenue growth because AML treatment is protocol- and sequencing-dependent; delayed use behind established mutation-specific therapies can extend time to treatment and lower the effective addressable population. Sell-side target reiterations do not resolve that execution question, and the next earnings release needs to show both new starts and persistence of demand rather than favorable annualization language.

The underappreciated competitive risk is not necessarily another menin inhibitor, but the fragmentation of NPM1-mutated AML into smaller biomarker-defined treatment pathways. That favors physicians’ familiar targeted regimens and may raise commercial-acquisition costs for SNDX; it also creates a relative read-through for KURA, whose NPM1-focused franchise faces the same sequencing constraints. Niktimvo-related collaboration revenue should be valued at a discount to proprietary product revenue until investors can separate recurring demand from partner ordering, milestones, and accounting timing.

Near term, SNDX can rebound sharply if third-quarter disclosures demonstrate that the second-quarter patient-start weakness was transient and management sustains 2027 revenue expectations without materially increasing cash burn. Over 6-18 months, the key structural catalyst is whether axatilimab data open a credible second commercial leg; failure would leave the equity dependent on a narrow hematology franchise and likely compress the revenue multiple despite a sizable cash buffer. Consensus appears too willing to extrapolate specialist enthusiasm into broad uptake, but the stock may also be overly discounted if starts reaccelerate before the market recognizes it.

Key Decisions for Investors

• Maintain a neutral/watch stance into SNDX third-quarter results; initiate a long only if Revuforj new patient starts reaccelerate sequentially and management reaffirms forward commercial guidance. A break below the prior-quarter run-rate or a guidance cut falsifies the near-term recovery thesis.
• For biotech risk capital, consider a 3-6 month SNDX/KURA relative-value monitor rather than an outright position: go long the company demonstrating superior prescription-start momentum after earnings, short the other only if comparable valuation and borrow permit. The trade isolates NPM1 market-growth assumptions from broader biotech beta.
• Do not underwrite Niktimvo collaboration revenue at the same multiple as recurring net sales until the company discloses the mix of product economics, milestones, and partner-related revenue. Treat a material sequential decline in collaboration revenue or higher operating-expense guidance as a cash-runway warning.
• Use the anticipated axatilimab Phase 2 readout as a defined catalyst only after confirming trial timing, endpoint, and options liquidity. Positive efficacy in idiopathic pulmonary fibrosis could create a second-leg valuation rerating; an inconclusive dataset would increase concentration risk in Revuforj and warrant reducing exposure.